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treatment improve endothelial dysfunction
and inhibit miRNA-155 in the erectile tissue
of the aged rat.
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Abstract
Background: Endothelial dysfunction underlies cardiovascular disease that frequently affects aged individuals.
Characterized by local decrease in nitric oxide, it results from down-regulation of endothelial nitric oxide synthase (eNOS)
expression/activity. Aiming to elucidate the molecular mechanisms involved in age-related endothelial dysfunction and
to unveil potential therapeutic targets, we tested how diet pattern, exercise and atorvastatin modulate the expression of
eNOS, inducible NOS (iNOS), endothelin-1, sirtuins (SIRT) and microRNA-155 in the erectile tissue of high-fat fed aged rats.
Methods: Sprague-Dawley male rats fed with high-fat diet until they completed 12 months were grouped and subjected
to energy restriction (ER), ER and atorvastatin, or, ER, atorvastatin and physical exercise. Controls were fed with standard
rodent chow. The blood pressure was measured using the tail-cuff method before sacrifice at 18 months. Glucose, total
cholesterol, HDL, triglyceride and CRP were assessed in blood and eNOS, endothelin-1, iNOS and sirtuins were detected
by immunofluorescence in the penis sections; eNOS, endothelin-1, iNOS, SIRT2–4 and SIRT6–7 were semi-quantified by
western blotting in tissue homogenates. MicroRNA-155 was quantified using RT-PCR in formalin-fixed paraffin embedded
sections. To compare the studied variables, two-tail student t test was used.
Results: Atorvastatin promotes eNOS expression and is more efficient than ER or exercise in the control of hyperlipidemia
and inflammation. Among the studied sirtuins, detected for the first time in the erectile tissue of the aged rat, SIRT2 aligns
with eNOS expression. Both proteins exhibit over-expression in animals with combined exercise, atorvastatin and ER.
Analysis of microRNA-155 expression also suggests its intervention in the regulation of eNOS expression. ER, particularly
when combined with atorvastatin, was able to reverse the increase of iNOS and endothelin-1 in high-fat fed rats.
Conclusions: The present results indicate that the association of ER, atorvastatin and exercise is more efficient than
isolated interventions in the prevention of endothelial dysfunction.
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Background
Ageing and obesity increase susceptibility to atherosclerosis
and cardiovascular diseases (CVD) [1]. The asymptomatic
antecedent of these entities that insidiously develop along
time, is endothelial dysfunction (ED) [2], which is charac-
terized by a decrease in bioavailability of nitric oxide (NO).
NO is a gaseous molecule, constitutively produced by
endothelial NO synthase (eNOS) in endothelial cells, that
diffuses into the smooth muscle cell (SMC) layer and in-
duces its relaxation [3]. Under pro-inflammatory condi-
tions, inducible NOS (iNOS) is activated, forming high
levels of NO and exhausting the substrate and co-factor
shared with eNOS. Additionally, high levels of iNOS-
derived NO interact with reactive oxygen species (ROS)
and cause oxidative damage. Opposite to NO, endothelin-1
(ET-1) is a powerful endothelium-derived vasoconstrictor
that contributes to ED and oxidative stress [4].
Decrease in eNOS-derived NO relates to functional
modifications that occur with variable extension in dif-
ferent vascular districts. The small vessels of the corpus
cavernosum (CC) of the penis are particularly susceptible
to endothelial structural/functional integrity loss [5, 6].
Hence, the CC constitutes a valuable feature to study
age- and diet-related vascular modifications [7, 8].
Several strategies may be considered to prevent age-
related ED, including diet modification, exercise or
pharmacological interventions. Energy restriction (ER), i.e.
reduced energy intake without malnutrition, counteracts
most age-related modifications in cells and individuals,
preserving endothelium-dependent dilation in rodents
through maintaining NO bioavailability [9]. Physical exer-
cise also has favorable effects on endothelial function
given its potent anti-inflammatory [10] and eNOS upregu-
latory functions [2].
Hydroxymethylglutaryl-coenzyme A reductase inhibi-
tors (statins), besides cholesterolemia-lowering effects,
seem to improve endothelial function. The exact mech-
anism is unclear but it seems to mitigate oxidative stress
conditions in vessel walls [11]. Statins stabilize eNOS
mRNA in endothelial cells, up-regulate eNOS activity
through PI3K-Akt-mediated Serine1177 phosphorylation
[12], reduce ET-1 production, exert anti-inflammatory
effects downregulating iNOS activation [13] and thus
ameliorate endothelial function [14].
Besides PI3K-Akt, other endogenous factors have been
recognized as modulators of eNOS activity. Sirtuin1, a
NAD+-dependent histone deacetylase, member of the
mammalian sirtuin family (SIRT1–7) activates eNOS
through deacetylation [15]. Recent evidence suggest that
sirtuins may act together to correct spontaneous acyl
modifications that occur under metabolic stress
conditions [16].
MicroRNAs (miRNAs) regulate gene expression by
binding preferentially to 3′-untranslated regions of
multiple targets. Nevertheless, miRNAs seem to have a
tissue- and cell-specific expression pattern. MiRNA-155
(miR-155) is constitutively expressed in endothelial cells
and extremely up-regulated in atherosclerotic plaques
[17]. In silico analysis suggest that eNOS mRNA may be
a direct target of miR-155. Moreover, simvastatin pre-
vented a decrease in eNOS expression, while decreasing
miR-155 levels, suggesting miR-155 intervention in the
simvastatin-induced increase of eNOS expression [18].
This study aimed to assess: a) SIRT1–7 and miR-155
expression in the CC of the aged rat; b) how diet pat-
tern, exercise and atorvastatin modulate SIRT1–7 and
miR-155 expression levels and; c) how miR-155 corre-




Twenty-five male Sprague-Dawley rats weighing 200-250 g
(Charles River, Barcelona, Spain) were housed individually
and kept under a controlled standard environment (12/
12 h light/dark cycle; 20–22 °C temperature; 40–60%
humidity) with free access to tap water throughout the
experiments.
At 2 months of age, the animals were divided into
experimental groups according to the flowchart. The
flowchart does not correspond to the previously submit-
ted. The upper arrows are not in the correct place.
Control group rats (C; n = 5) had free access to a
standard rodent chow with 4% of energy provided by fat,
mostly derived from fish (A04 Panlab®SL, Barcelona,
Spain) whereas high-fat diet (HF; n = 5) group had free
access to a purified rodent diet with 45% of energy from
fat derived from lard (58 V8 Test Diet®, Purina Mills®,
LLC, PMI Nutrition International®, Richmond, USA)
during 16 months.
The remaining 15 rats were maintained with free access
to HF diet during ten months and then were randomly di-
vided in three groups (n = 5). One group of rats was sub-
jected to a six-month period of energy restriction (ER),
consisting of 75% of the daily amount of standard rodent
chow consumed by the controls, individually adjusted to
body weight (HF/ER; n = 5); another group was submitted
to ER coupled with treatment with atorvastatin (Pfizer,
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New York, USA), orally administrated (5 mg/Kg of body
weight/day), a dose demonstrated to be sufficient to miti-
gate dyslipidemia and safe to use in the long-term [19]
(HF/ER/S; n = 5); and the third group was subjected to ER
coupled with the atorvastatin treatment and a 1 h swim 3
times per week [20] (HF/ER/S/Ex; n = 5).
By the 18th month, all animals were weighed and
sacrificed by decapitation after a 16 h fasting. The trunk
blood was collected, centrifuged (1000×g for 30 min at
4 °C) and the plasma was recovered and stored at − 80 °
C for biochemical determinations. The penises were ex-
cised and divided into two fragments: one was immedi-
ately stored at − 80 °C for molecular analysis and the
other was fixed in 10% buffered formaldehyde for im-
munofluorescence studies.
Blood pressure assessment
Systolic (SBP) and diastolic blood pressure (DBP) were
measured using the tail-cuff method in conscious rats
(LE5008-05PL, Panlab S.I., Barcelona, Spain) when they
completed 18 months of age. Measurements were made
10–15 min after acclimatization under restraining condi-
tions and were repeated in three consecutive days. Data
from the third day were considered valid.
Biochemical determinations
Plasma glucose concentrations were determined using a
glucose analyzer (OneTouch® Ultra™, Lifescan, Inc., Mil-
pitas, CA, USA) at the experimental end-point. Plasma
total cholesterol (TC), high-density lipoprotein choles-
terol (HDL-c) and triglyceride (TG) concentrations were
determined by enzymatic colorimetry in an Olympus®
auto-analyzer (Olympus America, Inc., NY, USA) resort-
ing to commercial kits (OSR6516, OSR6587, and
OSR61118, Olympus America, Inc., for TC, HDL-c and
TG, respectively). Low-density lipoprotein cholesterol
(LDL-c) levels were calculated by the formula of Friede-
wald (LDL-c = TC − [HDL-c − 1/5 TG], if serum TG is
400 mgdL− 1 or less) [21].
C-reactive protein (CRP) levels in serum were analyzed
with an immunoturbidimetric latex CRP assay, normal
set (OSR6199, Olympus America, Inc.).
Immunofluorescence
Briefly, after fixation for 24 h, the penis fragments were
dehydrated in a series of aqueous ethanol solutions with
increasing concentration, embedded in paraffin and ori-
ented along their transversal axis. Sections with thick-
ness of 4-6 μm were cut in a microtome (RM 2145,
Leica Microsystems GmbH, Germany) and placed on 0.
1% poly-L-lysine-coated microscopy slides. For immuno-
fluorescence (IF) detection of α-actin (a SMC marker),
eNOS, ET-1, iNOS, SIRT1, SIRT2, SIRT3, SIRT4, SIRT5,
SIRT6, and SIRT7, the penis sections were deparaffinized
in xylene, rehydrated in aqueous ethanol solutions (v/v)
with decreasing concentration (100%, 90% and 70%), ex-
posed to 1 M HCl solution for epitope retrieval, neutral-
ized with 0.1 M borax solution, followed by 1 h
incubation with blocking solution (1% w/v bovine serum
albumin (BSA) in phosphate-buffered saline, PBS). After-
wards, sections were incubated overnight at 4 °C with a
mixture of primary antibodies: rabbit anti-iNOS (Abcam,
Cambridge, UK) with goat anti-ET-1 (Santa Cruz Biotech-
nology, Inc., CA, USA); rabbit anti-eNOS (Santa Cruz Bio-
technology, Inc) with mouse anti-α-actin (Millipore,
Darmstadt, Germany); rabbit anti-SIRT1 (Santa Cruz
Biotechnology, Inc.) with goat anti-SIRT7 (Santa Cruz
Biotechnology, Inc.); and mouse anti-α-actin with
rabbit anti-SIRT2 (Sigma-Aldrich Co, Dorset, UK),
anti-SIRT3 (Cell Signaling Technology, MA, USA), anti-
SIRT4 (Sigma-Aldrich Co.), anti-SIRT5 (Sigma-Aldrich
Co.) or anti-SIRT6 (Sigma-Aldrich Co.) Negative controls
were performed without primary antibodies. After wash-
ing with PBS, the tissue sections were incubated for 1 h at
room temperature in a humidity chamber, with a suitable
mix of secondary antibodies diluted 0.05% (v/v), either
anti-rabbit conjugated with Alexa Fluor A488® (green) and
anti-goat conjugated with Alexa Fluor A568® (red) or
anti-mouse conjugated with Alexa Fluor A568® (red)
(Molecular Probes, Leiden, Netherlands). Nuclei were
counterstained with 4′,6-diamidino-2-phenylindole
(DAPI; blue) (Molecular Probes). Tissue sections were
then mounted in a buffered solution of glycerol and ob-
served in an ApoTome fluorescence microscope
(Imager. Z1, Carl Zeiss MicroImaging GmbH, Göttin-
gen, Germany). IF analysis was carried out in 3 different
animals of each experimental group and representative
images of each group were selected. All images were ac-
quired with AxionVision® software (Carl Zeiss MicroIma-
ging, GmbH).
Western blotting
For protein analysis, the penis fragments were mechan-
ically homogenized in lysis buffer (0.1 M NaCl, 5 mM
EDTA and 0.5% (v/v) Triton X-100 in 50 mM Tris pH 7.
2) supplemented with 0.5% (v/v) protease inhibitor cock-
tail (P8340, Sigma-Aldrich Co.) using a Polytron (Poly-
tron Pt 2500E, Kinematica, Switzerland) until the
residual fragments of the tissue had lost their reddish
color. After sonication for 15 min (Bioruptor™ UCD-200,
Diagenode, Belgium) and centrifugation at 12000 x g for
30 min, total protein quantification was performed for
each sample as described by Bradford (1976) [22] using
Bradford reagent (BioRad Laboratories, Hercules, CA,
USA). Absorbance was read at 595 nm in a Tecan Infin-
ite® 200 PRO microplate reader (Tecan, Männedorf,
Switzerland). Then, a total of 20 μg of protein from each
sample diluted in loading buffer was heated at 65 °C for
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30 min in a thermal shaker adjusted to 400 rpm (Ther-
momixer® 5436, Eppendorf Ibérica, Madrid, Spain),
followed by 5 min at 95 °C, centrifuged at 15000×g for
5 min (Eppendorf Ibérica), and then separated by so-
dium dodecylsulfate-polyacrilamide gel electrophoresis
(SDS-PAGE), using the discontinuous buffer system de-
scribed by Laemmli (1970) [23] and a 12% acrylamide
resolving gel (BioRad Laboratories) for approximately
1 h at room temperature under constant current of
25 mA. After electrophoresis, peptides were electrically
transferred to a nitrocellulose membrane with a pore
size of 0.45 μm (Trans-Blot® Transfer Medium BioRad
Laboratories) in a BioRad system, for 1 h and 30 min at
constant voltage (30 V). The peptides in the nitrocellu-
lose membrane were further reversibly stained with Pon-
ceau S solution and the image of the membrane was
captured in a ChemiDoc TM XRS (BioRad Laboratories).
The membrane was then washed, incubated first with
blocking solution (5% (w/v) of bovine serum albumin in
Tris buffer saline) and then with the aforementioned pri-
mary antibodies diluted in blocking solution for at least
48 h at 4 °C with constant agitation. After washing, the
membranes were incubated with the proper secondary
antibodies coupled with Horseradish Peroxidase (HRP)
diluted in blocking solution for 1 h at room temperature
with constant agitation. Next, the nitrocellulose mem-
branes were washed and the signal detection was per-
formed using a chemiluminescent peroxidase substrate
(Clarity™ Western ECL substrate, BioRad Laboratories).
Protein bands were visualized and the images captured
in a ChemiDocTM XRS apparatus (BioRad Laborator-
ies). Intensity of bands was quantified by densitometry
using the Image Lab® software (BioRad Laboratories).
Protein expression levels were normalized to the total
protein stain using Ponceau S in the respective lane.
Each experiment was repeated four times.
MicroRNA quantification by real-time polymerase chain
reaction
Total RNA extraction was performed using the commer-
cial Recover All™ Total Nucleic Acid Isolation Kit
(Ambion, Austin, Texas), according to the instructions of
the manufacturer with slight modifications, as proposed
by Liu and Xu [24]. In brief, for each sample, five
formalin-fixed paraffin embedded tissue sections (15 μm
thick) were cut in a microtome, using a fresh microtome
blade for each sample. Excess paraffin was trimmed and
each sample was deparaffinized in 100% xylene, washed
with 100% ethanol, and incubated with a protease for 2 h
at 50 °C, followed by 15 min at 75 °C to allow sample mix-
tures to clarify. After DNase digestion, 7 μL of total RNA
were used to generate cDNA using the MysticCq micro-
RNA cDNA synthesis Mix (Sigma-Aldrich Co.). In the
process of cDNA synthesis by reverse transcriptase (RT)
reaction, miRNAs were initially subjected to polyadenyla-
tion by poly (A) polymerase that catalyzed the transfer of
adenosine deoxynucleotides to the 3′-end of all RNAs, in-
cluding miRNAs. Then, the RNAs were converted into
cDNA by RT using an oligo-dT adaptor primer, incorpor-
ating a unique sequence at its 5′-end that would later be
recognized by a Universal primer, which allowed for the
amplification of cDNAs in real-time PCR reactions. Each
qPCR reaction mix consisted of 1 μL of RT product, 6 μL
SYBR Green (SYBR® Select Master Mix, Applied Biosys-
tems, CA, USA), 0.6 μL of lower Universal primer, 1 μL of
the upper primer for miR-155 (miScript Primer Assays for
miRNA-155-5p, Qiagen, Germany) and 3.4 μL of water.
Reactions were carried out in 96-well thin-wall PCR plates
in the StepOnePlus™ Real-time PCR system (Life Tech-
nologies, CA, USA). The amplification conditions were as
follows: 95 °C for 10 min; 95 °C for 15 s, 55 °C for 30s and
60 °C for 30s, for 42 cycles. All samples were run in dupli-
cate. The cDNA amount for each reaction was normalized
with the internal control RNU1A, using the RNU1A pri-
mer assay (Qiagen, Hilden, Germany). An amplification
reaction control without the RT enzyme (referred to as
-RT) was performed in order to discard a possible gen-
omic DNA contamination in the RNA solution. Relative
gene expression was calculated from the formula 2ΔCT
(ΔCT =CTRNU1A - CTtarget).
Statistical analysis
Results are presented as a mean value ± standard error
(SEM). To compare the studied variables, two-tail stu-
dent t test was used, considering p ≤ 0.05 as statistically
significant for every comparison.
Results
Body weight and blood pressure evaluation
Data relative to body weight and blood pressure of
groups C, HF and HF/ER were previously published [7].
For a better interpretation of the results they were in-
cluded in Table 1. No differences were observed
among C, HF and HF/ER groups regarding body
weight. However, treatment with ER and atorvastatin
(HF/ER/S) resulted in a reduction of the body weight
of rats at the experimental endpoint, compared to
both HF rats (p = 0.037), HF/ER (p = 0.005) and also
controls (p = 0.005). Exercise does not appear to have
additional effects relatively to ER associated with atorva-
statin. Regarding systolic and diastolic blood pressure
levels, group HF/ER/S/Ex presented lower levels of sys-
tolic blood pressure than HF/ER/S (p = 0.037), HF/ER
(p = 0.009) and HF (p = 0.001) groups. A decrease was
found in the diastolic blood pressure level in the HF/ER/S
group when compared to HF-treated rats (p = 0.003).
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Biochemical analysis
Blood levels of glucose, TC, HDL-c, LDL-c, TG and
CRP, of groups C, HF and HF/ER were previously pub-
lished [7] (Table1). Regarding glycemia, HF/ER and HF/
ER/S/Ex groups presents a decrease relatively to the HF-
treated animals (p = 0.010 and p = 0.011, respectively).
No other differences were verified among experimental
groups.
Broadly, our data indicate that atorvastatin treatment
was efficient in lowering blood TC, HDL-c and TG. HF/
ER/S and HF/ER/S/Ex groups presented TC levels lower
than those observed in HF/ER rats (p = 0.048 and
p = 0.027, respectively). TC levels in HF/ER/S/Ex animals
were lower when compared to the HF group (p = 0.048).
No differences were observed among groups for LDL-c
levels in blood, but a decrease in HDL-c levels in
atorvastatin-treated rats was found relatively to those in
the HF diet or HF/ER groups (p = 0.040 and p = 0.036
versus HF, and p = 0.043 and p = 0.013 versus HF/ER,
for HF/ER/S and HF/ER/S/Ex, respectively). Similarly, a
decrease in TG levels was observed in HF/ER/S when
compared to those treated with HF diet (p = 0.031) or
controls (p = 0.007). Exercise exerted an additional low-
ering effect on TG relatively to atorvastatin associated
with ER (p = 0.002).
CRP is an important marker of the inflammatory state.
Both HF/ER/S and HF/ER/S/Ex groups presented lower
levels of CRP than HF-treated rats (p = 0.005 and p < 0.
001, respectively) and controls (p = 0.047 and p = 0.010,
respectively). HF/ER/S also presented lower levels than
the HF/ER group (p = 0.020).
Dual immunolabeling of eNOS/α-actin; iNOS/ET-1; SIRT1/
SIRT7; SIRT2/α-actin; SIRT3/α-actin; SIRT4/ α-actin; SIRT5/
α-actin and SIRT6/ α-actin
Immunolabeling of α-actin confirmed the distribution of
SMC in the CC of the rat. The smooth muscle layer was
evident in animals from all experimental groups,
surrounding the endothelium (not labeled) and vascular
spaces. No marked differences among groups were evi-
dent (Fig.1a-e, Fig. 2f-j, Fig. 3a-j and Fig. 4a-j). Regarding
eNOS, this enzyme was detected in green not only in
the endothelium, but also in SMC, in line with previous
findings [8], apparently with higher intensity in HF/ER,
HF/ER/S and HF/ER/S/Ex rats (Figs. 1c-e). iNOS was
detected in the SMC in all the experimental groups
(Figs. 1f-j), being particularly evident in HF-treated rats
(Fig. 1g). On the other hand, ET-1 was mostly localized
in the endothelium, with an apparent higher intensity in
HF-fed animals (Fig. 1g). Sirtuins 1–7 were detected in
the erectile tissue of the rat in all the experimental con-
ditions (Figs. 2a-j, Figs. 3a-j and Figs. 4a-j). Except for
SIRT1, which has previously been identified [8], to the
best of our knowledge, the other isoenzymes were dem-
onstrated for the first time in the erectile tissue of the
rat in this study. SIRT1 was identified in the nucleus and
cytoplasm mainly in the SMC of all the analyzed tissues
(Figs. 2a-e), which agrees with our previous findings that
demonstrated the co-localization of SIRT1 and α-actin
[8]. SIRT7 was apparently more expressed in the endo-
thelium, presenting a distribution compatible with the
expected nucleolar localization (Figs. 2a-e). However,
cytoplasmic labeling for SIRT7 was also evident. This
pattern of distribution was previously detected in the
CC of human origin despite the higher expression of
SIRT7 observed in the SMC of human [25]. No marked
differences were seen among groups for SIRT1 and
SIRT7 expression. SIRT2 expression was observed in the
cytosol mainly in SMC in all experimental groups, often
co-localizing with α-actin labeling (Figs. 2f-j). This co-
localization seemed to be more intense in the CC from
rats of the HF/ER/S/Ex group (Fig. 2j). Mitochondrial
SIRT3, 4 and 5 were detected in the CC of all experi-
mental groups (Figs. 3a-j and Figs 4a-e). The punctuated
labeling, previously observed in the CC of human [25],
was better seen in SMC. Co-localization of SIRT3 or 4
Table 1 Body weight, blood pressure and biochemical determinations in blood
C HF HF/ER HF/ER/S HF/ER/S/Ex
Final body weight (g) 748.6 ± 33.8 888.8 ± 91.4 681.6 ± 16.1 584.4 ± 8.3*,#,+ 605.6 ± 15.2*,+
Systolic blood pressure (mmHg) 104.2 ± 2.0 128.6 ± 1.5 133.5 ± 6.3 130.3 ± 7.2* 104.6 ± 1.3#,+,$
Diastolic blood pressure (mmHg) 90.8 ± 3.4 103.6 ± 2.2 83.5 ± 5.6 79.3 ± 2.3# 82.8 ± 8.2
Glycemia (mg/dL) 105.2 ± 12.4 135.8 ± 5.4 111.0 ± 5.7# 129.5 ± 5.7 94.0 ± 2.8#
Total cholesterol (mg/dL) 104.0 ± 13.6 167.4 ± 20.3* 161.5 ± 12.9* 124.5 ± 10.4+ 88.2 ± 9.5#,+
HDL-c (mg/dL) 62.4 ± 7.5 85.4 ± 8.6 82.8 ± 4.3* 46.0 ± 10.8#,+ 46.8 ± 5.4#,+
LDL-c (mg/dL) 28.0 ± 11.0 40.6 ± 8.3 51.8 ± 10.7 33.3 ± 5.5 38.6 ± 3.1
Triglycerides (mg/dL) 155.3 ± 27.3 207.2 ± 40.8 150.0 ± 16.4 106.8 ± 4.6*,# 71.0 ± 5.2#,+,$
CRP (mg/L) 3.6 ± 0.5 8.4 ± 1.0* 3.6 ± 1.1# 1.8 ± 0.2*,#,+ 2.4 ± 0.1*,#
Data are presented as mean ± SEM. Data relative to groups C, HF and HF/ER were previously published [7]
C: controls; HF: high-fat; HF/ER: high fat/energy restriction; HF/ER/S: high-fat/energy restriction/statin;: high-fat/energy restriction/statin/exercise
*p < 0.05 vs C, # p < 0.05 vs HF, + p < 0.05 vs HF/ER, $p < 0.05 vs HF/ER/S
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and α-actin was more evident when compared to SIRT5
and α-actin, possibly because of the low levels of SIRT5
fluorescence (Figs. 4a-e). Regarding SIRT6, apart from
its nuclear labeling, a diffuse cytoplasmic labeling was
observed in the CC from rats from all groups (Figs 4f-j).
Semi-quantification of eNOS, iNOS, ET-1, SIRT2, SIRT3,
SIRT4, SIRT6 and SIRT7 by western blotting
Semi-quantification of the expression levels of the stud-
ied proteins was carried out by western blotting (Fig. 5).
For all the analyzed proteins, a band with the expected
molecular weight was identified (Fig. 5a). We verified
that the treatment for 6 months with atorvastatin alone
or coupled with exercise in rats under ER regimen, after
exclusive consumption of HF diet during 10 months,
(HF/ER/S and HF/ER/S/Ex groups, respectively) resulted
in an increment of eNOS expression, versus HF/ER (p =
0.016 and p = 0.006, respectively) or HF (p = 0.045 and
p = 0.017, respectively) groups (Fig. 5b). iNOS expres-
sion strongly increased in rats under HF diet consump-
tion relatively to the controls (p = 0.015). However, the
ER regimen associated or not with atorvastatin or exer-
cise (groups HF/ER, HF/ER/S and HF/ER/S/Ex) resulted
in a decrease of iNOS expression relatively to the HF
group (p = 0.003, p = 0.002 and p = 0.006, respectively)
(Fig. 5c). The differences in ET-1 expression among
Fig. 1 Dual immunolabeling of eNOS/α-actin (a-e) and iNOS/ET1 (f-j) in erectile tissue of rats from all experimental groups (n = 3/group). Smooth
muscle cells (SMC) layer was evident after α-actin labeling (red), surrounding endothelium (not labeled) and vascular spaces in all animals. No
marked differences among groups were evident. eNOS was detected not only in the endothelium, but also in SMC (green) apparently with higher
intensity in HF/ER, HF/ER/S and HF/ER/S/Ex groups (c-e). iNOS was detected in the SMC (green) in all experimental groups (f-j), being particularly
evident in HF-treated rats (g). ET-1 was mostly localized in the endothelium (red), with an apparent higher intensity in HF-fed rats (g). C-control;
HF-high-fat diet treated rats; HF/ER-high-fat diet treated rats under energy restriction for 6 months; HF/ER/S-high-fat diet treated rats under energy
restriction and atorvastatin treatment for 6 months; HF/ER/S/Ex-high-fat diet treated rats under energy restriction, atorvastatin treatment and
exercise for 6 months. VS- vascular space
Fig. 2 Dual immunolabeling of SIRT1/SIRT7 (a-e) and SIRT2/α-actin (f-j) in erectile tissue of rats from all experimental groups (n = 3/group). SIRT1
was identified in the nucleus and cytoplasm (green) mainly in the SMC of all the analyzed tissues (a-e) and SIRT7 is apparently more expressed in
the endothelium (red) (a-e). No marked differences were seen among groups for SIRT1 and SIRT7 expression. SIRT2 expression was observed in
cytosol mainly in SMC in all experimental groups, often co-localizing with α-actin labeling (f-j). The co-localization seems to be more intense in
CC from rats of HF/ER/S/Ex group (j). C-control; HF-high-fat diet treated rats; HF/ER-high-fat diet treated rats under energy restriction for 6 months;
HF/ER/S-high-fat diet treated rats under energy restriction and atorvastatin treatment for 6 months; HF/ER/S/Ex-high-fat diet treated rats under
energy restriction, atorvastatin treatment and exercise for 6 months. VS- vascular space
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experimental groups varied in an equivalent fashion
compared to those observed for iNOS, with an increase
in HF relatively to controls (p = 0.004), and a decrease in
HF/ER, HF/ER/S and HF/ER/S/Ex groups relatively to
the HF-fed rats (p = 0.013, p < 0.001 and p < 0.001, re-
spectively) (Fig. 5d).
Sirtuins expression was also analyzed. SIRT1 expression
in the rat CC was previously reported [8]. No differences
in groups treated with ER combined with atorvastatin or
exercise relatively to HF fed rats were found (Additional
file 1). SIRT2 expression levels increased in the CC of HF
rats relatively to controls (p = 0.011) (Fig. 5e). Exercise ap-
parently induced a strong effect in SIRT2 expression, tak-
ing into account that HF/ER/S/Ex presented the highest
levels (p < 0.001, relatively to HF, HF/ER and HF/ER/S)
(Fig. 5e). SIRT3 expression decreased in the CC of rats
treated with ER and atorvastatin (group HF/ER/S), rela-
tively to those under ER (HF/ER) (p = 0.020) (Fig. 5f). HF
diet increased SIRT4 expression when compared to con-
trols (p = 0.008) and none of the interventions used in this
study reversed this effect (Fig. 5g). By contrast, an incre-
ment in SIRT4 levels was seen in HF/ER/S/Ex, compared
to HF/ER/S rats (p = 0.023). SIRT6 expression increased
in HF-treated animals compared to controls (p = 0.005)
(Fig. 5h), an effect that was reversed by atorvastatin treat-
ment (p = 0.002 for HF versus HF/ER/S/Ex, and p < 0.001
for the other comparisons) (Fig. 5h). SIRT7 variation level
was similar to SIRT6 (Fig. 5i), increasing in HF when com-
pared to controls (p = 0.04) and decreasing in both groups
of atorvastatin-treated rats (HF/ER/S and HF/ER/S/Ex)
compared to HF (p = 0.011 and p = 0.023, respectively) or
HF/ER animals (p < 0.001 for both) (Fig. 5i).
Fig. 3 Dual immunolabeling of SIRT3/α-actin (a-e) and SIRT4/α-actin (f-j) in erectile tissue of rats from experimental groups (n = 3/group). Sirtuins
were labeled in green and α-actin in red. Mitochondrial SIRT3 and 4 were detected in co-localization with α-actin in the CC of all experimental
groups (a-j). C-control; HF-high-fat diet treated rats; HF/ER-high-fat diet treated rats under energy restriction for 6 months; HF/ER/S-high-fat diet
treated rats under energy restriction and atorvastatin treatment for 6 months; HF/ER/S/Ex-high-fat diet treated rats under energy restriction,
atorvastatin treatment and exercise for 6 months. VS- vascular space
Fig. 4 Dual immunolabeling of SIRT5/α-actin (a-e) and SIRT6/α-actin (f-j) in erectile tissue of rats from experimental groups (n = 3/group). Sirtuins
were labeled in green and α-actin in red. Mitochondrial SIRT 5 was detected in the CC of all experimental groups with low co-localization with
α-actin (a-e). SIRT6, apart from its nuclear labeling, presents a diffuse cytoplasmic labeling in all experimental groups (f-j). C-control; HF-high-fat
diet treated rats; HF/ER-high-fat diet treated rats under energy restriction for 6 months; HF/ER/S-high-fat diet treated rats under energy restriction
and atorvastatin treatment for 6 months; HF/ER/S/Ex-high-fat diet treated rats under energy restriction, atorvastatin treatment and exercise for
6 months. VS- vascular space
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MiRNA-155 quantification by real-time polymerase chain
reaction
On account of its apparent intervention in the regulation
of eNOS expression, miR-155 was quantified in the CC
of rats from all the experimental groups (Fig. 6). We
found no differences in miR-155 expression between rats
under HF diet and controls, but treatments with atorva-
statin or atorvastatin coupled with exercise decreased
the expression of miR-155 when compared to HF (p = 0.
049 and p = 0.011, for HF/ER/S and HF/ER/S/Ex, re-
spectively). No differences among HF/ER, HF/ER/S and
HF/ER/S/Ex were found.
Discussion
In previous studies, we demonstrated that long-term HF
consumption induces metabolic syndrome in aged rats
and that ER could be a non-pharmacological strategy to
mitigate most of HF-induced metabolic features [7]. In
addition, we found that HF significantly decreases eNOS
phosphorylation at Serine1177, likely compensated by an
upregulation of phosphorylation at Serine615, but without
NO production increment. An increase in systemic
inflammatory markers and upregulation of iNOS was also
observed [7, 8].
In the present study we demonstrated that additional
strategies, such as atorvastatin treatment or exercise
practice, coupled with ER are able to reduce body weight
relatively to controls, HF-treated animals and rats that
underwent ER for 6 months. As expected, association of
atorvastatin and exercise to ER, significantly diminished
the levels of circulating TC, HDL-c and TG. In fact,
while ER alone did not affect these parameters compara-
tively to rats exclusively fed with HF diet [7], its associ-
ation to atorvastatin treatment decreased TG, in
comparison to controls and HF rats, HDL-c compara-
tively to HF and HF/ER rats, and TC relatively to HF/ER
animals. Exercise promoted TG reduction, in agreement
with previous findings in rats under ER and swimming
Fig. 5 Semiquantification of protein expression levels of the eNOS, iNOS, ET-1, and SIRT2,3,4,6 and 7 by western blotting. Representative blots for each
studied protein and representative Ponceau S staining for samples of each group are ilustrated (a). Graphs (b-i) represent the densitometric quantification
of each band relatively to the respective lane after Ponceau S staining. C-control; HF-high-fat diet treated rats; HF/ER-high-fat diet treated rats under energy
restriction for 6 months; HF/ER/S-high-fat diet treated rats under energy restriction and atorvastatin treatment for 6 months; HF/ER/S/Ex-high-fat diet treated
rats under energy restriction, atorvastatin treatment and exercise for 6 months. Error bars represent standard error for the mean (n = 5/group). * p < 0.05 vs
C, # p< 0.05 vs HF, + p< 0.05 vs HF/ER, $p< 0.05 vs HF/ER/S
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[26]. In addition, atorvastatin ingestion reduced blood
CRP levels apart from intensifying the previously ob-
served anti-inflammatory effect of ER [7]. On the other
hand, exercise evidenced a predominant effect relatively
to statin treatment in lowering glycemia and systolic
blood pressure, in line with a recent report [27]. As ob-
served by others, atorvastatin did not affect blood glu-
cose regulation [28]. Taken together, our findings show
an overall beneficial effect owing both atorvastatin treat-
ment and exercise practice, when associated to ER in the
metabolic profile and inflammatory status of aged rats.
We found that atorvastatin alone or in association
with exercise not only induced up-regulation of eNOS,
but also led to a decline in the HF-induced upregulation
of ET-1. As well, ER alone was able to mitigate the over-
expression of both iNOS and ET-1. These findings agree
with previous data observed on vascular cultured cells
and aortas of aged rats [13, 29]. In line, a recent study in
the heart of obese diabetic mice supports the lowering
effect of exercise on iNOS expression [30], despite being
considered tissue-specific and dependent on the inten-
sity level [31]. Interestingly, exercise alone does not
seem to present lowering effects on ET-1, particularly in
aged individuals [32]. On the other hand, statins and ex-
ercise practice apparently up-regulate eNOS activity [33,
34]. We were not able to confirm eNOS phospho-
activation, taking into account that we did not assess
neither phospho-eNOS nor NO levels in CC in response
to atorvastatin or exercise, which would be of great
interest in order to evaluate their impact on endothelial
function.
Endothelial NOS plays a major relevance in endothe-
lial function. Besides Akt-mediated phosphorylation,
eNOS activity is modulated by SIRT1-catalysed deacety-
lation [15]. Our data relative to SIRT1 expression levels
in CC did not reveal correlations neither to eNOS levels,
nor to treatments. This was not an expected finding,
considering previous demonstrations of upregulation of
SIRT1 expression and activation by ER, statin and exer-
cise [1, 35, 36]. However, partially explaining our results,
a study in the aorta of aged rats failed to demonstrate
differences in either eNOS or SIRT1 expression with ER,
supporting that in aged animals, differences could be
more difficult to detect [37].
The inexistence of correlation between eNOS and
SIRT1 expression levels, prompted us to evaluate the ex-
pression of the other isoenzymes of the mammalian sir-
tuin family (SIRT2–7). Sirtuins exhibit a specific
localization in cells: SIRT1, 6 and 7 are predominantly
nuclear, SIRT3, 4 and 5 are mitochondrial and SIRT2 is
mainly cytosolic [38]. However, SIRT1, 3 and 7 can be
localized in the cytoplasm, SIRT2 and 3 in the nucleus
[8, 38–41] and, recently, SIRT5 and 6 were detected in
the cytosol [16]. All sirtuins deacetylate substrates in a
NAD+-dependent fashion [16] and the substrates are
often shared among the family members; p53 is a
common substrate of both SIRT1 and 7, NF-kB is com-
mon to SIRT1 and 6, and H4K16 is substrate of SIRT1,
2 and 3 [38–40, 42–44]. As well, all mitochondrial sir-
tuins, SIRT3, 4 and 5 intervene in the deacetylation of
acyl modifications that occur under metabolic stress, e.g.
in nutrient-derived energy imbalance [16]. This hypoth-
esis is based on the evidence that acyl-modifications
may occur by non-enzymatic processes in response to
high levels of acyl-Coenzyme A in the mitochondrial
matrix [45]. Our findings relative to the mitochondrial
sirtuins agree with a cooperative activation of transcrip-
tion of SIRT3 and 4, regarding the equivalent variation
of their levels in response to the experimental condi-
tions, despite the absence of significant differences. We
found a mild increase of SIRT3 and 4 in HF-treated rats,
intensified in rats submitted to ER, their decrease when
ER was associated with atorvastatin and an increase fol-
lowing exercise. Unfortunately, we did not observe levels
Fig. 6 Quantification of miR-155 in the CC of rats from all experimental groups. Relative gene expression was calculated from the formula 2ΔCT
(ΔCT = CTRNU1A - CTtarget).C-control; HF-high-fat diet treated rats; HF/ER-high-fat diet treated rats under energy restriction for 6 months; HF/ER/S-high-fat diet
treated rats under energy restriction and atorvastatin treatment for 6 months; HF/ER/S/Ex-high-fat diet treated rats under energy restriction, atorvastatin
treatment and exercise for 6 months. Error bars represent standard error for the mean (n = 4/group). * p< 0.05 vs C, # p< 0.05 vs HF
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of SIRT5 expression in a sufficient number of animals to
carry out statistical analysis.
The cardiovascular protective nuclear SIRT6 and 7 in-
creased substantially in the CC of rats under HF diet, and
SIRT7 decreased upon atorvastatin and exercise. An in-
crease in SIRT7 protein, but not SIRT6, in aged individ-
uals with CVD risk factors relatively to young ones has
previously been reported [25]. Whilst SIRT6 has been im-
plicated in the delay of ageing phenotype [46], DNA repair
[47], and in the prevention of inflammation, ED and car-
diac hypertrophy [48], SIRT7 is a major regulator of
nuclear-encoded genes involved in mitochondrial function
of cardiac cells [48, 49]. In view of the high-increase in
SIRT6 and 7 in HF diet-treated rats and their decrements
upon atorvastatin and exercise, their activation may in-
deed constitute a compensatory protective response.
Among the sirtuins, SIRT2 expression demonstrated a
variation in response to experimental conditions in the
rat CC that partially fits that observed for eNOS. In fact,
eNOS expression increases in rats treated with ER
coupled to atorvastatin and exercise, compared to HF
group. A gradually increased expression in HF/ER/S and
HF/ER/S/Ex groups was found for both eNOS and
SIRT2, suggesting not only their crosstalk in the CC, but
also that exercise and atorvastatin intervene in the regu-
lation of expression of SIRT2. Despite the lack of evi-
dence of a direct effect of SIRT2 on eNOS activation, its
role in the control of oxidative stress [50] indicates en-
hanced NO bioavailability. No previous evidence sug-
gests that atorvastatin or exercise, when individually
used, are able to up-regulate SIRT2 expression. An in
vitro study demonstrated that rosuvastatin does not pro-
mote SIRT2 expression in endothelial cells along 24 h
[35]. Also, SIRT2 expression did not increase in the skel-
etal muscle of female rats subjected to one-year volun-
tary running intervention [36]. However, no studies have
tested the association of statin and exercise effect on
SIRT2 expression. Additionally, we should take into con-
sideration that sirtuins present a cell-specific expression
and activity and that cells in CC could respond differen-
tially to pharmacological or non-pharmacological inter-
ventions relatively to skeletal muscle.
Changes on miR-155 expression in CC nearly opposed
the variations found for eNOS, which was expected in
view of the predicted affinity of miR-155 to eNOS mRNA
[18]. Previous evidence supporting that miR-155 promotes
atherosclerosis [17] and decreases endothelium-dependent
vasorelaxation through targeting eNOS [18], corroborates
our data. A decrease in miR-155 was found in groups
treated with ER and atorvastatin associated or not with ex-
ercise, but isolated HF diet or 6 months of ER after HF,
did not affect eNOS or miR-155 significantly, suggesting
that other contributers, besides diet pattern modification
are intervening. To the best of our knowledge, no evidence
of modulatory effect of atorvastatin, in contrast to simva-
statin [18], or exercise on miR-155 has been reported be-
fore. As miRNAs are major regulators of gene expression,
they are putative targets for cardiovascular diseases pre-
vention or therapy. Recent evidence associates other miR-
NAs with ED and particularly with the establishment of
erectile dysfunction in aged animals and diabetic patients
[51–53], which is promissory for the elucidation of the
molecular mechanisms associated with this group of
diseases.
Conclusion
Taken together our data demonstrated that among inter-
ventions to mitigate ED, atorvastatin is more efficient than
ER or exercise in controlling hyperlipidemia and inflam-
mation, as well as promoting eNOS expression in the CC.
Conversely, glycemia and blood pressure are predomin-
antly ameliorated by exercise. Additionally, it was found
that combined exercise, atorvastatin and ER treatments
increment expression of both SIRT2 and eNOS while de-
crease miR-155 levels in the CC of aged rats.
In conclusion, this study indicates that exercise, ator-
vastatin and ER in association have potential beneficial
effects on preventing ED in HF diet-treated aged rats.
Additional file
Additional file 1: Semiquantification of SIRT1 expression levels by
western blotting. The graph represent the densitometric quantification of
SIRT1 band relatively to the respective lane after Ponceau S staining.
Representative blots and Ponceau S staining for samples of each group
are shown. C-control; HFD-high-fat diet treated rats; HFD/ER-high-fat diet
treated rats under energy restriction for 6 months; HFD/ER+S-high-fat diet
treated rats under energy restriction and atorvastatin treatment for 6
months; HFD/ER+S+Ex-high-fat diet treated rats under energy restriction,
atorvastatin treatment and exercise for 6 months. Error bars represent
standard error for the mean (n=5/group). (PNG 135 kb)
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